HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) but lowers the price target from $10 to $9.
May 16, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Allogene Therapeutics but lowers the price target from $10 to $9.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100